CEPTOR SECURES $20.0 MILLION EQUITY COMMITMENT FROM FUSION CAPITAL

CepTor Corporation, Inc., a development-stage biopharmaceutical company focusing on cell targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago based institutional investor, whereby Fusion Capital has agreed to purchase up to $20.0 million of common stock. A more detailed description of the transaction is set forth in the Company's report on Form 8-K, recently filed with the SEC.
Genetic Engineering News